<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033227</url>
  </required_header>
  <id_info>
    <org_study_id>SN-SC-02-01</org_study_id>
    <nct_id>NCT01033227</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease</brief_title>
  <official_title>A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if administration of sodium nitrite is safe and can improve small
      vessel blood flow and tissue oxygenation when given as an additional treatment in patients
      with acute vaso-occlusive crisis (pain crisis) associated with sickle cell disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitric oxide (NO) is a naturally occuring chemical that relaxes blood vessels and helps
      improve blood flow.

      The pain associated with vaso-occlusive crisis (pain crisis) in sickle cell disease is caused
      in part by lack of oxygen and increased tissue acid because blood flow is blocked by stiff
      sickle red cells. Administration of sodium nitrite should generate nitric oxide in this area
      of hypoxia and acidosis and improve blood flow.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events</measure>
    <time_frame>48 hours from start of infusion</time_frame>
    <description>The primary end points will be to determine if a) a 48-hour sodium nitrite infusion is tolerated without a decrease in mean arterial blood pressure by 15mmHg for greater than 2 hours or development of methemoglobin greater than 5% and b) a 48-hour sodium nitrite infusion is safe as determined by monitoring for adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary End Point</measure>
    <time_frame>48 hours</time_frame>
    <description>a) reduced the duration and intensity of pain; b) reduced total narcotic analgesic consumption; and c) reduced length of hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>No drug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No study drug administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium nitrite injection, USP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration if sodium nitrite injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium nitrite injection, usp</intervention_name>
    <description>Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).</description>
    <arm_group_label>Sodium nitrite injection, USP</arm_group_label>
    <other_name>sodium nitrite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects meeting all of the following criteria will be considered for admission to the
        study:

          1. Male or female subject aged between 8 and 23 years of age; only patients up to the age
             of 23 will be studied at Childrens Hospital Los Angeles

          2. Electrophoretic diagnosis of sickle cell disease;

          3. Sudden onset of acute pain involving &gt;=1 sites typical of vaso-occlusive crisis
             (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest,
             abdomen, or back that can not be explained by other complications of sickle cell
             disease or by a cause other than sickle cell disease.);

          4. Severe pain requiring parenteral analgesics and hospitalization.

          5. Informed consent obtained from a legal representative or from subjects 18 years of age
             or older before enrollment;

          6. Being willing and able to be followed for at least 30 days for evaluation.

        Exclusion Criteria:

        Subjects presenting with any of the following will not be included in the study:

          1. Clinically significant bleeding;

          2. Current drug abuse or participation in methadone program;

          3. Episode of pain requiring hospitalization within 2 weeks prior to current admission;

          4. Other complications of sickle cell disease including cerebrovascular accident,
             pulmonary hypertension, or seizure;

          5. Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast
             feeding;

          6. Blood pressure less than 25th percentile for the subject's age and sex on admission or
             at the time of screening;

          7. Methemoglobinemia &gt;3%;

          8. Anemia with hemoglobin level less than 6 g/dL;

          9. Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;

         10. History of allergy to nitrites or allergy to other substances characterized by dyspnea
             and cyanosis;

         11. Treatment with allopurinol, a medication that could interfere with nitrite metabolism,
             within the past 30 days before screening;

         12. Treatment with any investigational drug within the past 30 days;

         13. Significant acute or chronic concomitant diseases (including renal, hepatic,
             cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary
             embolism) that would be inconsistent with survival for at least 6 months;

         14. Any subject judged by the clinical investigator or study manager to be inappropriate
             for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Coates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med. 2008 Apr 15;44(8):1506-28. doi: 10.1016/j.freeradbiomed.2008.01.008. Epub 2008 Jan 26. Review.</citation>
    <PMID>18261470</PMID>
  </reference>
  <reference>
    <citation>Mack AK, McGowan Ii VR, Tremonti CK, Ackah D, Barnett C, Machado RF, Gladwin MT, Kato GJ. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Haematol. 2008 Sep;142(6):971-8. doi: 10.1111/j.1365-2141.2008.07259.x. Epub 2008 Jul 11.</citation>
    <PMID>18671702</PMID>
  </reference>
  <reference>
    <citation>Lundberg JO, Weitzberg E. Nitrite reduction to nitric oxide in the vasculature. Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H477-8. doi: 10.1152/ajpheart.00611.2008. Epub 2008 Jun 27.</citation>
    <PMID>18586886</PMID>
  </reference>
  <reference>
    <citation>Hachiya T, Blaber AP, Saito M. Near-infrared spectroscopy provides an index of blood flow and vasoconstriction in calf skeletal muscle during lower body negative pressure. Acta Physiol (Oxf). 2008 Jun;193(2):117-27. Epub 2007 Dec 19.</citation>
    <PMID>18162057</PMID>
  </reference>
  <reference>
    <citation>Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008 Jan 5;371(9606):64-74. doi: 10.1016/S0140-6736(08)60073-2. Review.</citation>
    <PMID>18177777</PMID>
  </reference>
  <reference>
    <citation>Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007 Sep 15;110(6):2166-72. Epub 2007 May 29.</citation>
    <PMID>17536019</PMID>
  </reference>
  <reference>
    <citation>Vanin AF, Bevers LM, Slama-Schwok A, van Faassen EE. Nitric oxide synthase reduces nitrite to NO under anoxia. Cell Mol Life Sci. 2007 Jan;64(1):96-103.</citation>
    <PMID>17160351</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.</citation>
    <PMID>16291595</PMID>
  </reference>
  <reference>
    <citation>Ferreira LF, Harper AJ, Townsend DK, Lutjemeier BJ, Barstow TJ. Kinetics of estimated human muscle capillary blood flow during recovery from exercise. Exp Physiol. 2005 Sep;90(5):715-26. Epub 2005 May 20.</citation>
    <PMID>15908509</PMID>
  </reference>
  <reference>
    <citation>Raj A, Bertolone SJ, Mangold S, Edmonds HL Jr. Assessment of cerebral tissue oxygenation in patients with sickle cell disease: effect of transfusion therapy. J Pediatr Hematol Oncol. 2004 May;26(5):279-83.</citation>
    <PMID>15111778</PMID>
  </reference>
  <reference>
    <citation>Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med. 2004 Mar 15;36(6):707-17. Review.</citation>
    <PMID>14990351</PMID>
  </reference>
  <reference>
    <citation>Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med. 2003 May;9(5):496-500. Review.</citation>
    <PMID>12724752</PMID>
  </reference>
  <reference>
    <citation>Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO 3rd, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003 Dec;9(12):1498-505. Epub 2003 Nov 2.</citation>
    <PMID>14595407</PMID>
  </reference>
  <reference>
    <citation>Gladwin MT, Schechter AN, Shelhamer JH, Ognibene FP. The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1368-76. Review.</citation>
    <PMID>10228097</PMID>
  </reference>
  <reference>
    <citation>Lundberg JO, Gladwin MT, Ahluwalia A, Benjamin N, Bryan NS, Butler A, Cabrales P, Fago A, Feelisch M, Ford PC, Freeman BA, Frenneaux M, Friedman J, Kelm M, Kevil CG, Kim-Shapiro DB, Kozlov AV, Lancaster JR Jr, Lefer DJ, McColl K, McCurry K, Patel RP, Petersson J, Rassaf T, Reutov VP, Richter-Addo GB, Schechter A, Shiva S, Tsuchiya K, van Faassen EE, Webb AJ, Zuckerbraun BS, Zweier JL, Weitzberg E. Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol. 2009 Dec;5(12):865-9. doi: 10.1038/nchembio.260.</citation>
    <PMID>19915529</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <results_first_submitted>April 13, 2016</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2017</results_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Thomas Coates</investigator_full_name>
    <investigator_title>Hematology Division Head</investigator_title>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>pain crisis</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>nitrite</keyword>
  <keyword>vaso occlusive crisis</keyword>
  <keyword>pain medication</keyword>
  <keyword>sickled cells</keyword>
  <keyword>blood flow</keyword>
  <keyword>microcirculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited for the study during regular clinic visits.</recruitment_details>
      <pre_assignment_details>Once consent signed subjects would not be randomized into the treatment arm until (if or when) they had their admission to the hospital for vaso-occlusive crisis (VOC).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Drug</title>
          <description>This group did not receive anything additional in the no drug arm. The treatment group received the study drug and the non treatment group received no drug.</description>
        </group>
        <group group_id="P2">
          <title>Sodium Nitrite Injection, USP</title>
          <description>Administration if sodium nitrite injection, USP
sodium nitrite injection, usp: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Drug</title>
        </group>
        <group group_id="B2">
          <title>Sodium Nitrite Injection, USP</title>
          <description>Administration if sodium nitrite injection, USP
sodium nitrite injection, usp: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="15" upper_limit="17"/>
                    <measurement group_id="B2" value="15.5" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="B3" value="16" lower_limit="11" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sickle Cell Disease hb SS</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sbeta+thalassemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events</title>
        <description>The primary end points will be to determine if a) a 48-hour sodium nitrite infusion is tolerated without a decrease in mean arterial blood pressure by 15mmHg for greater than 2 hours or development of methemoglobin greater than 5% and b) a 48-hour sodium nitrite infusion is safe as determined by monitoring for adverse events</description>
        <time_frame>48 hours from start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Drug</title>
            <description>Will not receive study drug, there is no placebo in this study. The patient will know they are not receiving the study drug.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Nitrite Injection, USP</title>
            <description>Administration of sodium nitrite injection, USP</description>
          </group>
        </group_list>
        <measure>
          <title>48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events</title>
          <description>The primary end points will be to determine if a) a 48-hour sodium nitrite infusion is tolerated without a decrease in mean arterial blood pressure by 15mmHg for greater than 2 hours or development of methemoglobin greater than 5% and b) a 48-hour sodium nitrite infusion is safe as determined by monitoring for adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary End Point</title>
        <description>a) reduced the duration and intensity of pain; b) reduced total narcotic analgesic consumption; and c) reduced length of hospitalization.</description>
        <time_frame>48 hours</time_frame>
        <population>Data were *not collected* and the Outcome was never analyzed, study terminated</population>
        <group_list>
          <group group_id="O1">
            <title>No Drug</title>
            <description>No study drug administered</description>
          </group>
          <group group_id="O2">
            <title>Sodium Nitrite Injection, USP</title>
            <description>Administration if sodium nitrite injection, USP
sodium nitrite injection, usp: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary End Point</title>
          <description>a) reduced the duration and intensity of pain; b) reduced total narcotic analgesic consumption; and c) reduced length of hospitalization.</description>
          <population>Data were *not collected* and the Outcome was never analyzed, study terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after completion of study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Drug</title>
          <description>This group received no study drug and no placebo. They received standard of care treatment.</description>
        </group>
        <group group_id="E2">
          <title>Sodium Nitrite Injection, USP</title>
          <description>Administration if sodium nitrite injection, USP
sodium nitrite injection, usp: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Coates</name_or_title>
      <organization>Children's Hospital Los Angeles</organization>
      <phone>323 361 3841</phone>
      <email>TCoates@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

